Catalog No.
DVV00304
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
1.7 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN-10933, REGN10933, CAS: 2415933-42-3
Clone ID
Casirivimab
Casirivimab, PMID: 33226742
An EUA for casirivimab and imdevimab for COVID-19, PMID: 33451174
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, PMID: 33332778
Casirivimab, PMID: 34283490
Antibodies to watch in 2021, PMID: 33459118
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, PMID: 33037066
Imdevimab, PMID: 33226741
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic, PMID: 33253920
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents, PMID: 33388760
Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience, PMID: 33724242
Imdevimab, PMID: 34283431
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia, PMID: 34194882
Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, PMID: 34435337
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019, PMID: 34279629
Neutralizing Antibody Therapeutics for COVID-19, PMID: 33916927
Monoclonal antibodies for treating COVID-19, PMID: 33597176
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19, PMID: 34347950
In Translation: FcRn across the Therapeutic Spectrum, PMID: 33802650
Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro, PMID: 34223909
COVID-19: potential therapeutics for pediatric patients, PMID: 34458951
Real world utilization of REGEN-COV2 at a community hospital, PMID: 34364110
Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19, PMID: 33497123
Clinical Management of COVID-19: A Review of Pharmacological Treatment Options, PMID: 34071185
Reply to Puing et al, PMID: 34379766
Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19, PMID: 34393218
The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus, PMID: 33917138
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention, PMID: 34159344
Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2, PMID: 34422699
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies, PMID: 33794143
An EUA for bamlanivimab and etesevimab for COVID-19, PMID: 33830966
An EUA for sotrovimab for treatment of COVID-19, PMID: 34181630
The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5, PMID: 33758124
Post Acute Coronavirus (COVID-19) Syndrome, PMID: 34033370
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany, PMID: 34244967
An update to monoclonal antibody as therapeutic option against COVID-19, PMID: 33585808
Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report, PMID: 34405092
Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions, PMID: 34059561
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins, PMID: 34006961
Monoclonal Antibodies: Medical Uses for the Prevention and Treatment of Disease, PMID: 33861166
Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience, PMID: 34166513
Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection, PMID: 34159343
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients, PMID: 34258319
A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities, PMID: 33619724
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, PMID: 33495308
Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review, PMID: 34157890
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants, PMID: 34291118
Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia, PMID: 34332085
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines, PMID: 33724631
Rapid implementation of a new ambulatory infusion location for patients with COVID-19 to receive monoclonal antibody therapy, PMID: 33599712
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization, PMID: 34034784
For research use only. Not for human or drug use.
